Eton Pharmaceuticals, Inc. (ETON)
NASDAQ: ETON · Real-Time Price · USD
61.48
-1.95 (-3.07%)
Aug 19, 2026, 4:00 PM EDT - Market closed
Eton Pharmaceuticals Employees
Eton Pharmaceuticals had 44 employees as of December 31, 2025. The number of employees increased by 13 or 41.94% compared to the previous year.
Employees
44
Change (1Y)
13
Growth (1Y)
41.94%
Revenue / Employee
$2,399,886
Profits / Employee
$288,364
Market Cap
1.76B
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 44 | 13 | 41.94% |
| Dec 31, 2024 | 31 | 1 | 3.33% |
| Dec 31, 2023 | 30 | 2 | 7.14% |
| Dec 31, 2022 | 28 | 11 | 64.71% |
| Dec 31, 2021 | 17 | 1 | 6.25% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Bausch Health Companies | 20,300 |
| Perrigo Company | 8,100 |
| Trulieve Cannabis | 5,000 |
| Phibro Animal Health | 2,475 |
| HUTCHMED (China) | 1,790 |
| Alvotech | 1,279 |
| ANI Pharmaceuticals | 970 |
| Prestige Consumer Healthcare | 890 |
ETON News
- 2 days ago - Eton Pharmaceuticals participates in a conference call with Craig-Hallum - TheFly
- 3 days ago - Eton Pharmaceuticals reports Q2 non-GAAP EPS 43c, consensus 19c - TheFly
- 3 days ago - Eton Pharmaceuticals sees FY26 revenue exceeding $145M consensus $121.32M - TheFly
- 3 days ago - Eton Pharmaceuticals price target raised to $70 from $65 at H.C. Wainwright - TheFly
- 3 days ago - Eton Pharmaceuticals price target raised to $70 from $40 at B. Riley - TheFly
- 3 days ago - Eton Pharmaceuticals price target raised to $68 from $60 at Canaccord - TheFly
- 6 days ago - Eton Pharmaceuticals Earnings Call Transcript: Q2 2026 - Transcripts
- 6 days ago - Eton Pharmaceuticals Earnings release: Q2 2026 - Filings